阿尔茨海默病中脑脊液生物标志物与淀粉样蛋白正电子发射断层扫描之间的不一致为临床试验排除标准提供了线索。
Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer's Sheds Light on Clinical Trial Exclusion Criteria.
作者信息
Major Catherine K, Okhravi Hamid R
机构信息
Internal Medicine, Glennan Center for Geriatrics and Gerontology, Eastern Virginia Medical School, Norfolk, USA.
Internal Medicine: Geriatrics, Glennan Center for Geriatrics and Gerontology, Eastern Virginia Medical School, Norfolk, USA.
出版信息
Cureus. 2021 Feb 22;13(2):e13481. doi: 10.7759/cureus.13481.
Alzheimer's disease (AD) is the most common type of dementia and affects millions of adults over the age of 60 years. Accurate diagnosis relies on multiple modalities, including neuropsychological testing, cerebrospinal fluid (CSF) biomarkers, and amyloid positron emission tomography (PET) imaging. Discordant results between CSF biomarkers and amyloid PET can be seen in up to 15% of cases and can lead to exclusion from clinical trials along with anxiety and confusion for the patient and family. We present two cases of discordance (CSF+, amyloid PET-) that resulted in the exclusion of both patients from two large anti-amyloid monoclonal antibody trials.
阿尔茨海默病（AD）是最常见的痴呆类型，影响着数百万60岁以上的成年人。准确诊断依赖于多种方式，包括神经心理学测试、脑脊液（CSF）生物标志物和淀粉样蛋白正电子发射断层扫描（PET）成像。在高达15%的病例中可出现脑脊液生物标志物与淀粉样蛋白PET结果不一致的情况，这可能导致患者被排除在临床试验之外，并给患者及其家人带来焦虑和困惑。我们报告了两例结果不一致的病例（脑脊液阳性，淀粉样蛋白PET阴性），这导致两名患者均被两项大型抗淀粉样蛋白单克隆抗体试验排除。
Zotero 插件